Business Context and Reporting Period
Armata Pharmaceuticals, Inc. (ARMP) filed a Form 8-K Current Report dated December 1, 2025. The filing discloses the entry into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics and Transaction Details
- Agreement Type: Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC.
- Maximum Offering Size: Up to $100,000,000 in aggregate offering price of common stock.
- Commission: Up to 3.0% of gross sales proceeds payable to the sales agent.
- Additional Costs: The Company agreed to reimburse certain legal expenses incurred by the sales agent.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes Versus Prior Period
This filing represents a new corporate action rather than a comparative financial update. The material change is the authorization of a new mechanism to raise capital through the sale of shares on the NYSE American or other trading markets, subject to market conditions and the Company's discretion.
Guidance, Outlook, and Risks
- Discretionary Nature: The Company is not obligated to sell any shares, and the sales agent is not obligated to buy or sell any shares.
- Termination: Either party may terminate the agreement upon three days' notice.
- Constraints: Sales are limited by the number of shares registered on the effective Form S-3 and the number of authorized but unissued shares.
- Outlook: No specific financial guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the current number of authorized but unissued shares to determine the actual capacity for this offering.
- Review the effective Form S-3 (File No. 333-289585) to confirm the total shares registered and available for sale.
- Monitor future filings for actual sales activity and the impact of the 3.0% commission on net proceeds.
- Check the Company's most recent 10-K or 10-Q for current cash position and burn rate to assess the necessity of this capital raise.